BackLixte Biotechnology Holdings Overview

Lixte Biotechnology Holdings Receivables

Latest receivables for LIXT: $0.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer average

Loading

Lixte Biotechnology Holdings Receivables History

Loading

Lixte Biotechnology Holdings vs. peers: Receivables Comparison

Loading

Lixte Biotechnology Holdings Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Lixte Biotechnology Holdings (LIXT) FAQ

Lixte Biotechnology Holdings (LIXT) currently reports a receivables of $0 as of March 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Lixte Biotechnology Holdings's receivables history and peer comparisons.

Lixte Biotechnology Holdings's receivables changed from $0 to $0 (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Lixte Biotechnology Holdings reported $0 in receivables as of March 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current receivables of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Lixte Biotechnology Holdings, and consider following LIXT for alerts when major investors trade the stock.

Lixte Biotechnology Holdings is classified in the Healthcare sector. On receivables, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing LIXT with unrelated industries.